China approves use of Cuban drug to treat pancreatic cancer
Nimotuzumab, a medicine developed by Cuba’s Center for Molecular Immunology (CIM), was approved in China for the treatment of pancreatic cancer, after a phase III clinical study.
Radio Ciudad del Mar, desde Cienfuegos, Cuba
Radio Ciudad del Mar, productora de contenidos para la Radio e Internet, desde Cienfuegos, Cuba
🎧 Escúchenos en audio real
Nimotuzumab, a medicine developed by Cuba’s Center for Molecular Immunology (CIM), was approved in China for the treatment of pancreatic cancer, after a phase III clinical study.
With the arrival in Cuba of some quantities of financed supplies, and other efforts, drugs in high demand by the population are now in production, confirmed Rita Maria Garcia, director of Operations and Technology of the Biocubafarma Business Group.